Conversations in Neurology: New Agents and Strategies for Migraine and Related Headache Disorders Edition

Program Description

It has been well documented in the medical literature that despite the prevalence of migraine throughout the US population, several diagnostic and treatment gaps exist to this day. Despite these lingering performance gaps, insights into the pathophysiology of migraine and other related headache disorders have been advancing over the past decade or so, leading to 8 new medication approvals in just the past 2 years. None of these agents have been compared in head-to-head trials though many are from the same medication class, making the selection and sequence of abortive and preventive treatments for this population even more daunting.
 
To assist practicing neurologists in the development of contemporary diagnostic and treatment approaches for their patients, this activity features in-depth interviews with 2 internationally renowned headache specialists, Drs Peter Goadsby and Wade Cooper, presented in your choice of video or podcast format. These 2 experts delve into modern developments in both migraine and cluster headache. They also highlight key considerations in clinical decision making to aid in the recognition and management of these individuals.

Target Audience

This activity is intended for neurologists, nurse practitioners, physician assistants, and other providers involved in the care of patients with headache disorders.

Learning Objectives

  • Recognize the pros and cons of traditional diagnostic and therapeutic strategies in migraine in order to optimize the integration of modern advancements and improve clinical outcomes.
  • Review the therapeutic profiles associated with FDA-approved calcitonin gene-related peptide (CGRP) monoclonal antibodies for the prevention of episodic and chronic migraine and discern how and for whom these agents can be appropriately prescribed.
  • Describe the mechanisms of action and clinical profiles of recently approved abortive medications (e.g. ditans, gepants) for the management of migraine and identify individuals that may be candidates for these therapies.
  • Discuss the unique characteristics of cluster headache to facilitate its timely diagnosis and guide the use of existing and recently approved migraine treatments for this population.
  • Identify ongoing research strategies evaluating other novel agents and combination approaches for individuals suffering with various migraine presentations, and counsel appropriate patients about potential clinical trial participation.
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
Course opens: 
10/23/2020
Course expires: 
10/23/2021
Cost:
$0.00
Rating: 
0

Faculty 

 
  Peter Goadsby, MD, PhD, DSc
  Professor of Neurology, Director, Headache Center
  University of California, San Francisco
  San Francisco, California
  Professor of Neurology, Director, NIHR-Wellcome Trust King's Clinical Research Facility
  King's College London
  London, England
 
 
  Wade Cooper, DO
  Clinical Associate Professor of Neurology
  Clinical Associate Professor of Anesthesiology
  Director, Headache & Neuropathic Pain
  University of Michigan School of Medicine
  Ann Arbor, Michigan, United States
 
 

 

Moderator

 
  Ryan Smith, DO 
  Assistant Professor of Neurology
  Idaho College of Osteopathic Medicine
  Clinical Instructor
  University of Washington
  Director of Headache Medicine
  St Luke's Health System
  Boise, Idaho, United States

This activity is jointly provided by Postgraduate Institute for Medicine and Efficient LLC. 

 

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement
PIM designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)®. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures

Conflict of Interest Disclosure Policy

PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure

PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Faculty Disclosures

Dr Goadsby reports the following financial relationships: 
 
  • Consulting fees: Aeon Biopharma, Alder Pharmaceuticals, Allergan, Amgen, Biohaven Pharmaceuticals Inc., Clexio, Electrocore LLC, eNeura Inc., Epalex, GlaxoSmithKline, Impel Neuropharma, MundiPharma, Novartis, Pfizer, Santara Therapeutics, Teva Pharmaceuticals, Trigemina Inc., WL Gore
  • Contracted research: Amgen, Celgene
  • Stock options: Trigemina Inc.
  • Patent holder (licensed without fees): eNeura

Dr Cooper reports the following financial relationships:

  • Consulting fees: Amgen, Dolor Technologies, Lilly, Lundbeck, Teva, Theranica 
  • Ownership interest: Dolor Technologies
Dr Smith reports the following financial relationships: 
 
  • Consulting fees: Allergan
  • Fees for Non-CME/CE Services: Allergan, Amgen, Lilly, Teva  

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit  www.lillygrantoffice.com. 
 

Available Credit

  • 1.25 AMA PRA Category 1 Credit™

Price

Cost:
$0.00
Please login or register to take this course.